ArticleCommunications biology2026
A narrow developmental window defines PKN2's essential role in ventricular chamber morphogenesis.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A narrow developmental window defines PKN2's essential role in ventricular chamber morphogenesis.Communications biology · 2026Article
- Elucidating Gene Functions in Congenital Heart Disease.Current treatment options in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Protein kinase N2 (PKN2) is essential for embryonic heart development, but the precise timing and cellular requirement in cardiomyocytes are not well understood. Here we show that, in a constitutive cardiomyocyte-specific knockout (cKO) of PKN2, we observe partially penetrant early postnatal lethality, non-progressive systolic dysfunction in survivors, and a distinctive "coin-pouch" ventricular geometry resembling the embryonic shape, linking the phenotype to a developmental origin rather than ongoing pathology. By tracking heart morphogenesis, we find that mutant and control hearts are still grossly indistinguishable at E10.5, defining a stage prior to overt morphological divergence. Integrative RNA-seq, proteomics, and phosphoproteomics at E10.5 reveal transcriptional and proteomic signatures consistent with induction of actin cytoskeleton and motility-associated programs alongside repression of chromosome-condensation and mitotic modules in PKN2 cKO hearts. These molecular changes coincide with reduced cardiomyocyte proliferation at E10.5-E11.5 and early divergence in ventricular-shape trajectories. Quantitative light-sheet microscopy-based morphometrics of inducible cardiomyocyte-specific PKN2 knockout hearts pinpoints the critical dependence window: tamoxifen administration at E7.5 reproduces the ventricular geometry characteristic of constitutive PKN2 cKO hearts, whereas administration at E10.5 spares gross morphology. Together, these data show that cardiomyocytes depend on PKN2 during an early proliferative phase, characterized by cytoskeletal remodeling and motility-associated programs, that contributes to ventricular wall formation, after which PKN2 becomes dispensable for gross ventricular chamber morphogenesis. This temporally restricted requirement reconciles previous observations of PKN2's essential role in mesodermal and epithelial morphogenesis, suggesting a shared function in coordinating cytoskeletal remodeling with tissue expansion during organogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.